PDF(Pubmed)
Abstract：
BACKGROUND: Carbapenem antibiotics are a pivotal solution for severe infections, particularly in hospital settings. The emergence of carbapenem-resistant bacteria owing to the irrational and extensive use of carbapenems underscores the need for meticulous management and rational use. Clinical pharmacists, with their specialized training and extensive knowledge, play a substantial role in ensuring the judicious use of carbapenem. This study aimed to elucidate the patterns of carbapenem use and shed light on the integral role played by clinical pharmacists in managing and promoting the rational use of carbapenem antibiotics at Wenzhou Integrated Traditional Chinese and Western Medicine Hospital.
OBJECTIVE: To analyze carbapenem use patterns in our hospital and role of clinical pharmacists in managing and promoting their rational use.
METHODS: We performed a retrospective analysis of carbapenem use at our hospital between January 2019 and December 2021. Several key indicators, including the drug utilization index, defined daily doses (DDDs), proportion of antimicrobial drug costs to total hospitalization expenses, antibiotic utilization density, and utilization rates in different clinical departments were comprehensively analyzed.
RESULTS: Between 2019 and 2021, there was a consistent decline in the consumption and sales of imipenem-cilastatin sodium, meropenem (0.3 g), and meropenem (0.5 g). Conversely, the DDDs of imipenem-cilastatin sodium for injection increased in 2020 and 2021 vs 2019, with a B/A value of 0.67, indicating a relatively higher drug cost. The DDDs of meropenem for injection (0.3 g) exhibited an overall upward trend, indicating an increasing clinical preference. However, the B/A values for 2020 and 2021 were both > 1, suggesting a relatively lower drug cost. The DDDs of meropenem for injection (0.5 g) demonstrated a progressive increase annually and consistently ranked first, indicating a high clinical preference with a B/A value of 1, signifying good alignment between economic and social benefits.
CONCLUSIONS: Carbapenem use in our hospital was generally reasonable with a downward trend in consumption and sales over time. Clinical pharmacists play a pivotal role in promoting appropriate use of carbapenems.
OBJECTIVE: To analyze carbapenem use patterns in our hospital and role of clinical pharmacists in managing and promoting their rational use.
METHODS: We performed a retrospective analysis of carbapenem use at our hospital between January 2019 and December 2021. Several key indicators, including the drug utilization index, defined daily doses (DDDs), proportion of antimicrobial drug costs to total hospitalization expenses, antibiotic utilization density, and utilization rates in different clinical departments were comprehensively analyzed.
RESULTS: Between 2019 and 2021, there was a consistent decline in the consumption and sales of imipenem-cilastatin sodium, meropenem (0.3 g), and meropenem (0.5 g). Conversely, the DDDs of imipenem-cilastatin sodium for injection increased in 2020 and 2021 vs 2019, with a B/A value of 0.67, indicating a relatively higher drug cost. The DDDs of meropenem for injection (0.3 g) exhibited an overall upward trend, indicating an increasing clinical preference. However, the B/A values for 2020 and 2021 were both > 1, suggesting a relatively lower drug cost. The DDDs of meropenem for injection (0.5 g) demonstrated a progressive increase annually and consistently ranked first, indicating a high clinical preference with a B/A value of 1, signifying good alignment between economic and social benefits.
CONCLUSIONS: Carbapenem use in our hospital was generally reasonable with a downward trend in consumption and sales over time. Clinical pharmacists play a pivotal role in promoting appropriate use of carbapenems.
摘要：
背景：碳青霉烯类抗生素是治疗严重感染的关键解决方案，特别是在医院环境中。由于碳青霉烯类抗生素的不合理和广泛使用，碳青霉烯类耐药细菌的出现强调了对精细管理和合理使用的必要性。临床药师,凭借他们的专门培训和广泛的知识，在确保碳青霉烯的明智使用方面发挥重要作用。本研究旨在阐明碳青霉烯类抗生素的使用模式，并阐明临床药师在管理和促进温州市中西医结合医院碳青霉烯类抗生素的合理使用中发挥的整体作用。
目的：分析我院碳青霉烯类药物的使用模式及临床药师在管理和促进其合理使用中的作用。
方法：我们对2019年1月至2021年12月在我院使用碳青霉烯的情况进行了回顾性分析。几个关键指标，包括药物利用指数，定义的每日剂量（DDDs），抗菌药物费用占总住院费用的比例，抗生素利用密度，并对不同临床科室的使用率进行综合分析。
结果：在2019年至2021年之间，亚胺培南-西司他丁钠的消费量和销售额持续下降，美罗培南（0.3克），和美罗培南（0.5克）。相反，2020年和2021年注射用亚胺培南-西司他丁钠的DDDs与2019年相比有所上升,B/A值为0.67,表明药物成本相对较高.注射用美罗培南(0.3g)的DDDs总体呈上升趋势,表明临床偏好增加。然而,2020年和2021年的B/A值均>1，表明药物成本相对较低。注射用美罗培南（0.5g）的DDDs呈逐年递增趋势，始终排名第一，表明临床偏好较高，B/A值为1，表明经济效益和社会效益之间具有良好的一致性。
结论：我院使用碳青霉烯类药物总体上是合理的，随着时间的推移，其消费量和销售额呈下降趋势。临床药师在促进碳青霉烯类抗生素的合理使用中起着举足轻重的作用。
目的：分析我院碳青霉烯类药物的使用模式及临床药师在管理和促进其合理使用中的作用。
方法：我们对2019年1月至2021年12月在我院使用碳青霉烯的情况进行了回顾性分析。几个关键指标，包括药物利用指数，定义的每日剂量（DDDs），抗菌药物费用占总住院费用的比例，抗生素利用密度，并对不同临床科室的使用率进行综合分析。
结果：在2019年至2021年之间，亚胺培南-西司他丁钠的消费量和销售额持续下降，美罗培南（0.3克），和美罗培南（0.5克）。相反，2020年和2021年注射用亚胺培南-西司他丁钠的DDDs与2019年相比有所上升,B/A值为0.67,表明药物成本相对较高.注射用美罗培南(0.3g)的DDDs总体呈上升趋势,表明临床偏好增加。然而,2020年和2021年的B/A值均>1，表明药物成本相对较低。注射用美罗培南（0.5g）的DDDs呈逐年递增趋势，始终排名第一，表明临床偏好较高，B/A值为1，表明经济效益和社会效益之间具有良好的一致性。
结论：我院使用碳青霉烯类药物总体上是合理的，随着时间的推移，其消费量和销售额呈下降趋势。临床药师在促进碳青霉烯类抗生素的合理使用中起着举足轻重的作用。
